![Space-time analysis of ovarian cancer mortality rates by age groups in spanish provinces (1989–2015) | BMC Public Health | Full Text Space-time analysis of ovarian cancer mortality rates by age groups in spanish provinces (1989–2015) | BMC Public Health | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12889-020-09267-3/MediaObjects/12889_2020_9267_Fig1_HTML.png)
Space-time analysis of ovarian cancer mortality rates by age groups in spanish provinces (1989–2015) | BMC Public Health | Full Text
Distribution of ovarian cancer patients according to the age at diagnosis. | Download Scientific Diagram
![Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients | Scientific Reports Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-55515-x/MediaObjects/41598_2019_55515_Fig1_HTML.png)
Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients | Scientific Reports
Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia | PLOS ONE
![Ovarian, Fallopian Tube and Primary Peritoneal Cancer (including Borderline) (Chapter 10) - Gynaecological Oncology for the MRCOG Ovarian, Fallopian Tube and Primary Peritoneal Cancer (including Borderline) (Chapter 10) - Gynaecological Oncology for the MRCOG](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180510054848968-0632:9781316986844:63871fig10_1.png?pub-status=live)
Ovarian, Fallopian Tube and Primary Peritoneal Cancer (including Borderline) (Chapter 10) - Gynaecological Oncology for the MRCOG
![Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial - The Lancet Oncology Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/b83343ff-8cfa-437b-996b-f0d1f61b1841/gr1.jpg)
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial - The Lancet Oncology
![Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis | BMC Cancer | Full Text Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6139-6/MediaObjects/12885_2019_6139_Fig1_HTML.png)